Close up shot of vaccines - glass bottles, ampules and syringe with needle. Good for illustration of flu shot, vaccination and covid-19
Our Work

Latham & Watkins Advises on IO Biotech’s US$75 Million Private Placement Financing

August 7, 2023
Firm represents the placement agents in the financing.

IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, has announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately US$75 million, before deducting offering expenses.

Latham & Watkins LLP advised the placement agents in the private placement with a New York capital markets team led by partners Nathan Ajiashvili and Alison Haggerty, with associates Kathleen Mehary, Angel Marcial, and Erin Gilgen.